Neon Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch NTGN and buy or sell other stocks, ETFs, and their options commission-free!About NTGN
BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials.
CEOHugh O'Dowd, MBA
CEOHugh O'Dowd, MBA
Employees—
Employees—
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2013
Founded2013
Employees—
Employees—
NTGN Key Statistics
Market cap88.93M
Market cap88.93M
Price-Earnings ratio-1.14
Price-Earnings ratio-1.14
Dividend yield—
Dividend yield—
Average volume665.16K
Average volume665.16K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$5.97
52 Week high$5.97
52 Week low$0.88
52 Week low$0.88
Stock Snapshot
With a market cap of 88.93M, Neon Therapeutics(NTGN) trades at $3.07. The stock has a price-to-earnings ratio of -1.14.
On 2025-12-14, Neon Therapeutics(NTGN) shares started trading at —, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 665.16K.
The stock's 52-week range extends from a low of $0.88 to a high of $5.97.
The stock's 52-week range extends from a low of $0.88 to a high of $5.97.
People also own
Based on the portfolios of people who own NTGN. This list is generated using Robinhood data, and it’s not a recommendation.